Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients - The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study
Pm. Okin et al., Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients - The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study, HYPERTENSIO, 35(1), 2000, pp. 13-18
Citations number
28
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Obesity may limit sensitivity of ECG voltage criteria for left ventricular
hypertrophy (LVH) because of the attenuating effects of increased body mass
on precordial voltages. However, obesity is associated with an increased p
revalence of anatomic LVH, making more accurate ECG criteria in obese patie
nts a clinical priority. ECG LVH by Cornell voltage-duration product and/or
Sokolow-Lyon voltage criteria was used to select patients for the Losartan
Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Clinical
and ECG data were available in 8417 patients (54% women; mean age, 67+/-7
years); 2519 were overweight and 1573 were obese by gender-specific body ma
ss index criteria. Increased body mass index had significant but directiona
lly opposite effects on ECG LVH by these 2 criteria. Compared with normal-w
eight patients, obese and overweight patients had lower Sokolow-Lyon voltag
e and a lower prevalence of ECG LVH by Sokolow-Lyon criteria (10.9% versus
16.2% versus 31.4%; P<0.001). In contrast, obese and overweight patients ha
d higher mean values of the Cornell product and higher prevalences of ECG L
VH by this criterion (75.1% versus 69.9% versus 60.7%; P<0.001). After adju
stment for age, gender, race, myocardial infarction, and diastolic and puls
e pressure with the use of logistic regression analysis, increased body mas
s remained highly predictive of the presence of ECG LVH. Compared with norm
al-weight patients, obese patients had a >2-fold higher risk of ECG LVH by
the Cornell product but a 4-fold lower risk of ECG LVH by Sokolow-Lyon volt
age; overweight status was associated with intermediate risks, with a 151%
greater likelihood of ECG LVH by the Cornell product but only 44% of the ri
sk of LVH by Sokolow-Lyon voltage criteria compared with normal-weight indi
viduals. Thus, Sokolow-Lyon voltage criteria underestimate the prevalence o
f anatomic LVH in the presence of obesity, whereas Cornell product criteria
for ECG LVH appear to provide a more accurate measure of LVH in obese and
overweight patients.